In addition to LLL12B, other direct STAT3 inhibitors such as TTI-101 (C188-9) [24], LYW-6 [25], and dual-site inhibitors like compound 4c [26] have shown promising antitumor effects in early-phase clinical or preclinical studies, further underscoring the therapeutic relevance of targeting STAT3 across cancer types. This evidence concerns the gene STAT3 and cancer.